SONATA-MS

Treatment tested

• Ocrelizumab

  B-lymphocyte antigen CD20 binding agent

Other measures (7)

Inclusion Criteria: * Diagnosis of RRMS according to the revised McDonald criteria (2017 or 2024 revisions). * Initiation of ocrelizumab s.c in accordance with routine clinical practice and local prescribing information. * The decision to initiate ocrelizumab s.c. has been made by the treating physician prior to and independently of study participation. * Willingness to complete the patient-reported outcome questionnaire TASQ, where applicable. Exclusion Criteria: * Participation in any clinical study involving disease modifying therapies for multiple sclerosis during the study period or at the time of enrollment. * Prior treatment with rituximab. * Contraindications to ocrelizumab as per the local prescribing information. * Severe psychiatric or cognitive impairment that, in the opinion of the treating physician, would preclude informed consent, reliable participation in the study, or completion of patient-reported outcomes. * Any condition which, in the opinion of the treating physician, would interfere with participation in the study or the interpretation of study results. * For participants participating in a Market Research and Patient Support Program (MAP), inclusion is permitted only when a cross-reference to the unique MAP patient identifier is available.

The main purpose of the study is to assess patient-reported satisfaction with subcutaneous (s.c.) ocrelizumab administration in participants with relapsing-remitting multiple sclerosis (RRMS) who are treatment-naive, switching from intravenous (i.v.) ocrelizumab to s.c. ocrelizumab, or switching from a prior disease-modifying therapy (DMT) to s.c. ocrelizumab.